Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: November 9, 2009.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. E9–27435 Filed 11–13–09; 8:45 am]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Center for Scientific Review Special Emphasis Panel, December 4, 2009, 8 a.m. to December 4, 2009, 7 p.m., Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD, 20814 which was published in the Federal Register on November 2, 2009, 74 FR 56652–56653.

The meeting will be held at The Renaissance M Street Hotel, 1143 New Hampshire Avenue, NW., Washington, DC 20037. The meeting date and time remain the same. The meeting is closed to the public.

Dated: November 9, 2009.

Anna Snouffer,

Deputy Director, Office of Federal Advisory Committee Policy.

[FR Doc. E9–27433 Filed 11–13–09; 8:45 am] BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of the Director, National Institutes of Health; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the Recombinant DNA Advisory Committee.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

Name of Committee: Recombinant DNA Advisory Committee.

Date: December 1-2, 2009.

Time: December 1, 2009, 9 a.m. to 5:30 p.m.; December 2, 2009, 8:30 a.m. to 4:15 p.m.

Agenda: The Recombinant DNA Advisory Committee will review and discuss selected human gene transfer protocols as well as related data management activities. Protocols to be reviewed include a protocol for Leber congenital amaurosis using an AAV vector, a protocol for adenosine deaminase severe combined immunodeficiency disease (ADA SCID) using a lentiviral vector and a protocol for alpha 1 antitrypsin deficiency using an AAV vector. Additional discussions include an update on a trial that used a lentiviral vector for beta-thalassemia and sickle cell disease and a discussion of proposed final changes to the NIH Guidelines for Research Involving Recombinant DNA to address synthetic nucleic acids. Finally, an experiment involving the introduction of tetracycline resistance into non-ocular strains of Chlamydia trachomatis will be discussed as required under Section III-A-1 of the NIH Guidelines for Research Involving Recombinant DNA Molecules. Further information on this research can be found in the October 28, 2009 Federal Register (74 FR 55568). An agenda for the meeting will be available on the OBA Web site (http:// oba.od.nih.gov/rdna rac/rac meetings.html).

Place: National Institutes of Health, Natcher Building, 45 Center Drive, Bethesda, MD 20892.

Contact Person: Laurie Lewallen, Advisory Committee Coordinator, Office of Biotechnology Activities, National Institutes of Health, 6705 Rockledge Drive, Room 750, Bethesda, MD 20892–7985, 301–496–9839, Lewallenl@od.nih.gov.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

Information is also available on the Institute's/Center's home page: http://oba.od.nih.gov/rdna/rdna.html, where an agenda and any additional information for the meeting will be posted when available.

OMB's "Mandatory Information
Requirements for Federal Assistance Program
Announcements" (45 FR 39592, June 11,
1980) requires a statement concerning the
official government programs contained in
the Catalog of Federal Domestic Assistance.
Normally NIH lists in its announcements the
number and title of affected individual
programs for the guidance of the public.
Because the guidance in this notice covers
virtually every NIH and Federal research
program in which DNA recombinant
molecule techniques could be used, it has
been determined not to be cost effective or

in the public interest to attempt to list these programs. Such a list would likely require several additional pages. In addition, NIH could not be certain that every Federal program would be included as many Federal agencies, as well as private organizations, both national and international, have elected to follow the NIH Guidelines. In lieu of the individual program listing, NIH invites readers to direct questions to the information address above about whether individual programs listed in the Catalog of Federal Domestic Assistance are affected.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research Generally; 93.39, Academic Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, Undergraduate Scholarship Program for Individuals from Disadvantaged Backgrounds, National Institutes of Health, HHS)

Dated: November 9, 2009.

Anna Snouffer,

Deputy Director, Office of Federal Advisory Committee Policy.

[FR Doc. E9–27485 Filed 11–13–09; 8:45 am] BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Request for Information on Source Capture Ventilation Systems (SCVS) Units for Use in Nail Salons, Including Downdraft Vented Nail Tables and Portable SCVS

AGENCY: National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Request for information.

SUMMARY: The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) is conducting an evaluation of source capture ventilation systems (SCVS) units for use in nail salons, including downdraft vented nail tables and portable SCVS. This notice invites developers, manufacturers, distributors, and vendors of downdraft vented nail tables and portable nail salon SCVS that feature local exhaust recirculation to submit new, unused units for evaluation. A supply of filters sufficient to provide ventilation during 6 months of daily operation (as recommended by the developer or manufacturer), should

be submitted to the NIOSH laboratory in Cincinnati, OH, together with the table or portable SCVS.

Operational characteristics and effectiveness in reducing levels of a source point tracer gas at standard distances from the vent will be evaluated. Evaluation parameters for the units will include, but are not limited to: Airflow and capture characteristics, and noise level. A separate evaluation of filters when new and at intervals of use will also be conducted. Manufacturers, distributors, vendors and developers who wish to submit units with filters for evaluation are invited to respond to this announcement. A report on each unit submitted for evaluation, including feedback on the evaluation parameters and staff recommendations, will be sent to the submitter. Results of the evaluation will potentially be used to develop educational materials for nail technicians and may also be disseminated through reports, publications, presentations, or other media. NIOSH does not intend to identify manufacturers in its publications, but testing information referencing particular manufacturers would be releasable if requested under the Freedom of Information Act.

DATES: The deadline for receipt of downdraft vented nail table and portable SCVS unit (with filters) submissions at NIOSH is February 28, 2010. A written description of the units must be submitted prior to table shipment (see SUPPLEMENTARY INFORMATION below). Evaluations will begin subject to the dates submissions are received. The SCVS will be retained

begin subject to the dates submissions are received. The SCVS will be retained for up to 10 months while being evaluated, after which they will be returned.

ADDRESSES: Manufacturers, distributors, vendors, and developers who wish to submit downdraft vented nail table or portable SCVS units with filters for evaluation are invited to respond to this notice by sending a written reply to Susan Reutman, NIOSH, Robert A. Taft Laboratories, MS–C23, 4676 Columbia Parkway, Cincinnati, OH 45226 or e-mail SReutman@cdc.gov.

SUPPLEMENTARY INFORMATION: Please respond to Susan Reutman regarding intent to submit a unit and the written unit description, including the manufacturer, schedule of availability of the unit and filters for evaluation, and a statement of the terms under which the SCVS will be made available for evaluation, and shipment date. Shipping and handling costs (including insurance) to ship the table or portable SCVS units to NIOSH and for NIOSH to return the units to the submitter will be

the responsibility of the submitter. NIOSH reserves the right to decide which submissions will be evaluated based on compliance with the specifications described above. NIOSH also reserves the right not to proceed in this manner.

Note: As a government entity, we cannot endorse any specific product directly, indirectly, or by implication. NIOSH will not be responsible for any costs related to usage, wear and tear or accidental damage to the downdraft table or portable SCVS units during transport or while they are at NIOSH. Used filters will not be returned or replaced by NIOSH.

FOR FURTHER INFORMATION CONTACT:

Susan Reutman, NIOSH, Robert A. Taft Laboratories, MS–C23, 4676 Columbia Parkway, Cincinnati, OH 45226, telephone (513) 533–8286.

Dated: November 6, 2009.

John Howard,

Director, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention.

[FR Doc. E9–27387 Filed 11–13–09; 8:45 am] BILLING CODE 4163–19–P

DEPARTMENT OF HOMELAND SECURITY

Office of the Secretary

[Docket No. DHS-2009-0135]

DHS Data Privacy and Integrity Advisory Committee

AGENCY: Privacy Office, DHS.
ACTION: Notice of Federal Advisory

Committee meeting.

SUMMARY: The DHS Data Privacy and Integrity Advisory Committee will meet on December 3, 2009, in Washington, DC. The meeting will be open to the public.

DATES: The DHS Data Privacy and Integrity Advisory Committee will meet on Thursday, December 3, 2009, from 8:30 a.m. to 2 p.m. Please note that the meeting may end early if the Committee has completed its business.

ADDRESSES: The meeting will be held at 490 L'Enfant Plaza, SW., (L'Enfant Plaza East, Suite 3207) Washington, DC. Written materials, requests to make oral presentations, and requests to have a copy of your materials distributed to each member of the Committee prior to the meeting should be sent to Martha K. Landesberg, Executive Director, DHS Data Privacy and Integrity Advisory Committee, by November 23, 2009. Persons who wish to submit comments and who are not able to attend or speak at the meeting may submit comments at

any time. All submissions must include the Docket Number (DHS–2009–0135) and may be submitted by any *one* of the following methods:

• Federal eRulemaking Portal: http://www.regulations.gov. Follow the instructions for submitting comments.

• *E-mail: PrivacyCommittee@dhs.gov.* Include the Docket Number (DHS–2009–0135) in the subject line of the message.

• Fax: (703) 483–2999.

• *Mail:* Martha K. Landesberg, Executive Director, Data Privacy and Integrity Advisory Committee, Department of Homeland Security, Washington, DC 20528.

Instructions: All submissions must include the words "Department of Homeland Security Data Privacy and Integrity Advisory Committee" and the Docket Number (DHS–2009–0135). Comments will be posted without alteration at http://www.regulations.gov, including any personal information provided.

Docket: For access to the docket to read background documents or comments received by the DHS Data Privacy and Integrity Advisory Committee, go to http://www.regulations.gov.

FOR FURTHER INFORMATION CONTACT:

Martha K. Landesberg, Executive Director, DHS Data Privacy and Integrity Advisory Committee, Department of Homeland Security, Washington, DC 20528, by telephone (703) 235–0780, by fax (703) 235–0442, or by e-mail to *PrivacyCommittee@dhs.gov*.

SUPPLEMENTARY INFORMATION: Notice of this meeting is given under the Federal Advisory Committee Act (FACA), 5 U.S.C. App. (Pub. L. 92-463). During the meeting, the Chief Privacy Officer will provide the DHS Data Privacy and Integrity Advisory Committee an update on the activities of the DHS Privacy Office. The Committee will also hear reports on the DHS Privacy Office's **Electronic Complaint Tracking System** and on other matters related to DHS redress programs generally. In addition, the Committee's subcommittees will discuss their ongoing work. The agenda will be posted in advance of the meeting on the Committee's Web site at http:// www.dhs.gov/privacy. Please note that the meeting may end early if all business is completed.

If you wish to attend the meeting, the DHS Privacy Office encourages you to register in advance by contacting Martha K. Landesberg, Executive Director, DHS Data Privacy and Integrity Advisory Committee, at

 $\label{lem:privacyCommittee} Privacy Committee @dhs.gov. \ Advance \\ registration is voluntary. \ The Privacy$